Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation

BACKGROUND: China has the highest prevalence of hepatitis B virus (HBV) infection worldwide. Universal HBV screening might enable China to reach the WHO 2030 target of 90% diagnostics, 80% treatment, and 65% HBV-related death reduction, and eventually elimination of viral hepatitis. We evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Shu, Wong, William CW, Zou, Zhuoru, Cheng, Dan Dan, Ong, Jason J, Chan, Polin, Ji, Fanpu, Yuen, Man-Fung, Zhuang, Guihua, Seto, Wai-Kay, Zhang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789560/
https://www.ncbi.nlm.nih.gov/pubmed/35063115
http://dx.doi.org/10.1016/S2214-109X(21)00517-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789560/
https://www.ncbi.nlm.nih.gov/pubmed/35063115
http://dx.doi.org/10.1016/S2214-109X(21)00517-9

Ejemplares similares